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Abstract
Background: In the Systolic Hypertension in Europe trial (NCT02088450), we investigated whether systolic blood pressure
variability determines prognosis over and beyond level.
Methods: Using a computerised random function and a double-blind design, we randomly allocated 4695 patients ($60
years) with isolated systolic hypertension (160–219/,95 mm Hg) to active treatment or matching placebo. Active treatment
consisted of nitrendipine (10–40 mg/day) with possible addition of enalapril (5–20 mg/day) and/or hydrochlorothiazide
(12.5–25.0 mg/day). We assessed whether on-treatment systolic blood pressure level (SBP), visit-to-visit variability
independent of the mean (VIM) or within-visit variability (WVV) predicted total (n = 286) or cardiovascular (n= 150) mortality
or cardiovascular (n= 347), cerebrovascular (n= 133) or cardiac (n= 217) endpoints.
Findings: At 2 years, mean between-group differences were 10.5 mm Hg (p,0.0001) for SBP, 0.29 units (p = 0.20) for VIM,
and 0.07 mm Hg (p = 0.47) for WVV. Active treatment reduced (p#0.048) cardiovascular (228%), cerebrovascular (240%)
and cardiac (224%) endpoints. In analyses dichotomised by the median, patients with low vs. high VIM had similar event
rates (p$0.14). Low vs. high WVV was not associated with event rates (p$0.095), except for total and cardiovascular
mortality on active treatment, which were higher with low WVV (p#0.0003). In multivariable-adjusted Cox models, SBP
predicted all endpoints (p#0.0043), whereas VIM did not predict any (p$0.058). Except for an inverse association with total
mortality (p = 0.042), WVV was not predictive (p$0.15). Sensitivity analyses, from which we excluded blood pressure
readings within 6 months after randomisation, 6 months prior to an event or both were confirmatory.
Conclusions: The double-blind placebo-controlled Syst-Eur trial demonstrated that blood-pressure lowering treatment
reduces cardiovascular complications by decreasing level but not variability of SBP. Higher blood pressure level, but not
higher variability, predicted risk.
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Introduction
Whether blood pressure variability determines prognosis over
and beyond level needs further clarification. Recent publications
[1–4], reviewed elsewhere [5,6] suggested that clinicians might
reduce stroke incidence more by targeting systolic blood pressure
variability along with level, preferentially using calcium-channel
blockers [1–4], which might result in less blood pressure variability
than other antihypertensive drugs classes. These recommenda-
tions, not endorsed by current guidelines [7], largely originated
from observational population studies [8,9] or from clinical trials
[2] or cohort studies that exclusively enrolled high-risk patients
with diabetes mellitus [10,11], a history of stroke or transient
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ischaemic attack [2], or renal failure [12–14]. Other methodolog-
ical issues that might have confounded the issue are categorisation
of continuous variability measures for risk prediction [2,9], the
application of variability indexes that are dependent on blood
pressure level [2,9], and the limitation of endpoints to mortality
[9,13].
The double-blind Systolic Hypertension in the Elderly Trial
(Syst-Eur) demonstrated that among older patients with isolated
systolic hypertension, antihypertensive drug treatment starting
with the calcium-channel blocker nitrendipine reduced the rate of
stroke and cardiovascular complications [15,16]. By analysing the
Syst-Eur database, we investigated in a double-blind fashion
whether placebo vs. active treatment starting with a dihydropyr-
idine calcium-channel blocker differentially affected visit-to-visit
and within-visit blood pressure variability and whether visit-to-visit
or within-visit variability had an additive role to blood pressure
level in predicting outcome.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Protocol S1 and
Checklist S1.
Ethics Statement
The protocol of this trial [16,17] and the procedure to obtain
informed consent were approved by the ethics committees of the
University of Leuven and the 198 participating centres. We used
the principles outlined in the Helsinki declaration [18]. At
enrolment in the run-in period of the trial, all patients provided
written informed consent. Investigators confirmed that they had
obtained consent from patients in a checklist of inclusion and
exclusion criteria, which they had to submit to the coordinating
office before a patient could be randomised.
Figure 1. Trial profile.
doi:10.1371/journal.pone.0103169.g001
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Data Availability Statement
Bayer AG funded investigator-initiated Syst-Eur trial (1988-
1997). The corresponding author owns the data and funding by
Bayer does therefore in no way alter our adherence to PLOS ONE
policies on sharing data and materials.
Selection of patients
Previous publications describe the Syst-Eur protocol, inclusion
and exclusion criteria, and procedures for recruitment and
randomisation [15–17]. Eligible patients were at least 60 years
old. On masked placebo, during the run-in phase, their sitting
systolic blood pressure ranged from 160 mm Hg to 219 mm Hg,
their sitting diastolic blood pressure was below 95 mm Hg, and
their standing systolic blood pressure was at least 140 mm Hg. All
patients consented to be enrolled. The blood pressure determining
eligibility was the average of six sitting and six standing readings,
two in each position at three baseline visits, 1 month apart. Of
8926 screened patients, 6403 (71.7%) entered the run-in period,
and 4695 (52.6%) were randomised (figure 1).
Treatment and follow-up procedures
After stratification by centre, sex, and previous cardiovascular
complications, eligible patients were randomly assigned to
treatment with active medication or placebo. A computerised
random function generated at the study coordinating centre in
Leuven without block size restriction ensured random allocation of
patients at the 198 participating centres. The study medications
were stepwise titrated and combined to reduce sitting systolic
blood pressure by 20 mm Hg or more to levels below 150 mm Hg.
Active treatment was initiated with nitrendipine (10–40 mg/day).
If necessary, the dihydropyridine calcium-channel blocker was
combined with or replaced by enalapril maleate (5–20 mg/day),
hydrochlorothiazide (12.5–25 mg/day), or both drugs. Placebo
tablets were identical to the study drugs with a similar schedule.
Patients who withdrew from double-blind treatment proceeded to
supervised open follow-up. During double-blind and supervised
open follow-up, patients had their sitting blood pressure measured
twice at 3-monthly intervals. The two measurements were
averaged for analysis of blood pressure level. Terminal digit and
number preference were monitored during the trial [19]. Patients
for whom regular follow-up was not possible proceeded to non-
Table 1. Patient characteristics by fourths of the distribution of systolic blood pressure at randomisation.
Characteristic Categories of systolic blood pressure p
Limits, mm Hg ,166.2 166.3–171.7 171.8–179.2 $179.3
Number of subjects (%)
All patients in category 1142 1206 1166 1181
Women 764 (66.9) 785 (65.1) 763 (65.4) 826 (69.9)* 0.049
Smokers 78 (6.8) 85 (7.1) 83 (7.1) 97 (8.2) 0.58
Drinking alcohol 354 (31.0) 345 (28.6) 309 (26.5) 287 (24.3) 0.0023
Previous cardiovascular complications 270 (23.6) 358 (29.7){ 359 (30.8) 415 (35.1)* ,0.0001
Antihypertensive treatment 410 (36.1) 519 (43.1)` 603 (51.7)1 662 (56.2)* ,0.0001
Diabetes mellitus 100 (8.8) 116 (9.6) 119 (10.2) 157 (13.3)* 0.0027
Mean (SD) of characteristic
Age (years) 69.4 (6.5) 69.7 (6.3) 70.5 (6.8){ 71.4 (7.0){ ,0.0001
Body mass index (kg/m2) 26.9 (3.9) 27.0 (4.0) 26.9 (4.1) 27.3 (4.3){ 0.019
Heart rate (beats per minute) 72.6 (7.7) 73.1 (7.8) 73.4 (7.9) 73.4 (8.5) 0.074
Serum total cholesterol (mmol/l) 5.96 (1.14) 6.06 (1.17)* 6.03 (1.27) 6.01 (1.20) 0.21
Serum HDL cholesterol (mmol/l) 1.39 (0.43) 1.40 (0.42) 1.39 (0.45) 1.41 (0.45) 0.48
Blood glucose (mmol/L) 5.31 (1.36) 5.43 (1.45)* 5.43 (1.45) 5.58 (1.57)* 0.0002
Serum creatinine (mmol/L) 85.7 (17.8) 87.5 (18.1)* 88.5 (19.0) 89.9 (19.9) ,0.0001
Between-visit blood pressure variability
Standard deviation (mm Hg) 4.9 (4.4) 5.6 (4.0)1 6.8 (5.0)1 8.2 (6.2)1 ,0.0001
Coefficient of variation (%) 3.0 (2.7) 3.3 (2.4){ 3.9 (2.8)1 4.4 (3.2)1 ,0.0001
Variability independent of mean (units) 6.1 (5.6) 6.2 (4.4) 6.6 (4.8)* 6.3 (4.7) 0.084
Maximum minus minimum (mm Hg) 9.3 (8.4) 10.7 (7.7)1 12.9 (9.6)1 15.6 (11.7)1 ,0.0001
Average real variability (mm Hg) 6.0 (5.8) 7.1 (5.7)1 8.2 (6.4)1 10.0 (8.2)1 ,0.0001
Within-visit variability (mm Hg)
Averaged absolute difference 3.0 (2.4) 3.3 (2.6)* 3.4 (2.9) 3.9 (3.2)1 ,0.0001
The p values denote the significance of the differences in prevalence rates or means across fourths of the distribution of systolic blood pressure at randomisation. The
value of x to calculate VIM based on six blood pressure readings, two at each of three visits was 3.347. Significance of the difference with the adjacent lower fourth:
*p#0.05;
{p#0.01;
`p#0.001;
1p,0.0001.
doi:10.1371/journal.pone.0103169.t001
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supervised open follow-up that involved collecting information on
vital status, occurrence of major endpoints and other events, and
the use of antihypertensive medications at annual intervals.
Patients without any report within the year before the trial
stopped were counted as lost to follow-up.
Definition of endpoints
The main endpoints included death, stroke, myocardial
infarction, and congestive heart failure. Stroke, the primary
endpoint, was a neurological deficit with symptoms continuing for
more than 24 h or leading to death with no apparent cause other
than vascular. Acute myocardial infarction required two of the
Figure 2. Systolic blood pressure level and variability at randomisation and during follow-up. SBP (A), VIM (B) and WVV (C) denote
systolic blood pressure, visit-to-visit variability independent of the mean and within-visit variability. Values at randomisation and at annual intervals
during follow-up were derived from at least six blood pressure readings, two at each of three consecutive visits. The blood pressure level at six
months is the average of four blood pressure readings at two consecutive visits. The computation of variability requires at least three visits. Variability
is therefore not plotted at 6 months. P values indicate the significance of the average between-group difference throughout follow-up.
doi:10.1371/journal.pone.0103169.g002
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following three disorders: typical chest pain, electrocardiographic
changes, or increased cardiac enzymes, and did not include silent
myocardial infarction. Congestive heart failure required the
presence of three disorders: symptoms, such as dyspnoea, clinical
signs, such as ankle oedema or crackles, and the necessity of
treatment with diuretics, vasodilators, or antihypertensive drugs.
Figure 3. Blood pressure and variability at randomisation and during follow-up among patients staying on monotherapy. SBP (A),
VIM (B) and WVV (C) denote systolic blood pressure, visit-to-visit variability independent of the mean and within-visit variability in 2236 patients
staying on monotherapy with the first-line study medication. Values at randomisation and at annual intervals during follow-up are derived from at
least six blood pressure readings, two at each of three consecutive visits. The blood pressure level at six months is the average of four blood pressure
readings at two consecutive visits. The computation of variability requires at least three visits. Variability is therefore not plotted at 6 months. P values
indicate the significance of the average between-group difference throughout follow-up.
doi:10.1371/journal.pone.0103169.g003
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Sudden death encompassed any death of unknown origin
occurring immediately or within 24 h of the onset of acute
symptoms, as well as unattended death for which no likely cause
could be established by necropsy or medical history. Cardiac
events included fatal and non-fatal heart failure, fatal and non-
fatal myocardial infarction, and sudden death. The endpoint
committee, which was unaware of the patients’ treatment status,
identified all major endpoints by reviewing the patients’ files and
Figure 4. Blood pressure and variability at randomisation and during follow-up among patients proceeding to combination
therapy. SBP (A), VIM (B) and WVV (C) denote systolic blood pressure, visit-to-visit variability independent of the mean and within-visit variability in
2459 patients proceeding to combination therapy. Values at randomisation and at annual intervals during follow-up are derived from at least six
blood pressure readings, two at each of three consecutive visits. The blood pressure level at six months is the average of four blood pressure readings
at two consecutive visits. The computation of variability requires at least three visits. Variability is therefore not plotted at 6 months. P values indicate
the significance of the average between-group difference throughout follow-up.
doi:10.1371/journal.pone.0103169.g004
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other source documents, or by requesting detailed written
information from the investigators, or by both approaches. The
number of endpoints in the present analysis rests on the update
published in 1999 [16].
Sample size
Our original sample-size calculations assumed a rate of stroke in
the placebo group of 17.0 events per 1000 patient-years. 15 000
patient-years (i.e., 3000 patients with an average follow-up of 5
years) were required to detect a 40% change in the overall stroke
rate with a two-tailed significance of 1% and 90% power [17]. A
one-year pilot trial was concluded on 30 September 1989, and
showed that the protocol could be followed and that the logistics of
the trial were feasible. The Ethics Committee therefore imple-
mented the full study on 1 February 1990. On August 18, 1995,
the projected number of patients had been recruited [15].
However, because in the early phase of the study the stroke rate
in the placebo group was only 13.6 events per 1000 patient-years,
the steering committee decided in January, 1996, to continue
recruitment through 1996 or until at least 4000 patients had been
randomly assigned treatment. The steering committee stopped the
trial prematurely on February 18, 1997, after the second interim
analysis, because of a significant benefit of active treatment on the
incidence of stroke [15].
Statistical analysis
For database management and statistical analysis, we used the
SAS system, version 9.3 (SAS Institute Inc., Cary, NC).
Significance was a two-tailed a-level of 0.05 or less. Means and
proportions were compared using the large-sample z-test or
ANOVA and Fisher’s exact test, respectively.
Assessment of blood pressure level and variability. We
limited our analyses to systolic blood pressure, because in middle-
aged and older subjects it is a stronger risk factor than diastolic
blood pressure is [20]. Henceforth, blood pressure refers to systolic
blood pressure. We assessed associations between level and
variability of blood pressure using Pearson correlation coefficients
and changes in continuous measurements using a large sample z-
test.
We determined blood pressure level (SBP) and variability
separately for the run-in period in 4695 patients and after
randomisation in 2297 and 2398 patients randomised to placebo
or active treatment, respectively. We assessed visit-to-visit blood
pressure variability from the variability independent of the mean
(VIM) [2], the standard deviation (SD), the coefficient of variation
(CV), the difference between maximum and minimum blood
pressure (MMD) [2], and average real variability (ARV) [21]. To
compute visit-to-visit variability, we averaged the two blood
pressure readings obtained at each visit over the period of analysis.
SD is the within-patient standard deviation of the blood pressure
values. CV is SD divided by the mean. MMD is the absolute
difference between the highest and lowest blood pressure recorded
at any visit during follow-up. VIM is calculated as the SD divided
by the mean to the power x and multiplied by the population
mean to the power x [2]. The power x is obtained by fitting a
curve through a plot of SD against mean using the model SD = a
6meanx, where x was derived by non-linear regression analysis as
implemented in the PROC NLIN procedure of the SAS package.
ARV is the average of the absolute differences between blood
pressure measurements obtained at consecutive visits. ARV
averages the absolute blood pressure differences between consec-
utive visits and thereby accounts for the order according to which
blood pressure was measured
ARV~
1
N{1
XN{1
k~1
DBPkz1{BPk D
where k ranges from 1 to N–1, and N is the number of blood
pressure readings [21].
Within-visit variability (WVV) is the absolute difference
between the two blood pressure measurements at each visit
averaged over the whole follow-up of each patient [1].
Analysis of outcome. We compared the incidence of the
pre-defined endpoints between groups, using the log-rank test for
rates and Kaplan-Meier survival function estimates. We used Cox
regression to compute hazard ratios, while stratifying for centre
and adjusting for randomisation group (if applicable), sex, age,
body mass index, heart rate, serum total cholesterol, smoking and
Table 2. Incidence of endpoints by randomisation group.
Rate per 1000 patient-years Relative difference with
Endpoint (number of endpoints) rate in placebo group
Placebo Active % rate p value
(n = 2297) (n = 2398) (95% CI)
Mortality
Total 25.1 (148) 22.3 (138) 211 (229 to 13) 0.34
Cardiovascular 13.9 (82) 11.0 (68) 221 (243 to 9) 0.15
Fatal plus non-fatal cardiovascular endpoints
All 34.7 (196) 25.0 (151) 228 (242 to 211) 0.0022
Stroke 14.0 (81) 8.5 (52) 240 (257 to 215) 0.0045
Cardiac endpoints 20.9 (120) 15.9 (97) 224 (242 to 20.3) 0.048
Heart failure 9.2 (53) 6.7 (41) 227 (251 to 10) 0.13
Myocardial infarction 8.4 (48) 6.4 (39) 223 (250 to 17) 0.22
Cardiac endpoints included fatal and non-fatal myocardial infarction, fatal and non-fatal heart failure, and sudden death. Significance was derived from the log-rank test.
doi:10.1371/journal.pone.0103169.t002
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Figure 5. Incidence of total mortality by treatment group and median of blood pressure variability. VIM (A) and WVV (B) denote visit-to-
visit variability independent of the mean and within-visit variability of systolic blood pressure. P and A indicate placebo and active treatment,
respectively, and 50% refers to the median. On placebo (n= 2297) and active treatment (n= 2398), x values used to compute VIM were 0.822 and
0.628; medians were 9.36 and 9.60 units for VIM, and 2.83 and 2.91 mm Hg for WVV. P value indicates the significance of the log-rank test comparing
low with high variability within each randomisation group.
doi:10.1371/journal.pone.0103169.g005
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Figure 6. Incidence of cardiovascular mortality by treatment group and median of blood pressure variability. VIM (A) and WVV (B)
denote visit-to-visit variability independent of the mean and within-visit variability of systolic blood pressure. P and A indicate placebo and active
treatment, respectively, and 50% refers to the median. On placebo (n= 2297) and active treatment (n= 2398), x values used to compute VIM were
0.822 and 0.628; medians were 9.36 and 9.60 units for VIM and 2.83 and 2.91 mm Hg for WVV. P value indicates the significance of the log-rank test
comparing low with high variability within each randomisation group.
doi:10.1371/journal.pone.0103169.g006
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Figure 7. Incidence of the composite cardiovascular endpoint by treatment group andmedian of blood pressure variability. VIM and
WVV denote visit-to-visit variability independent of the mean and within-visit variability. The number of analysed patients randomised to placebo and
active treatment was 2297 and 2398, respectively. P and A indicate placebo and active treatment, respectively, and 50% refers to the median. On
placebo and active treatment, x values used to compute VIM were 0.995 and 0.718; medians were 9.34 and 9.58 units for VIM and 2.82 and 2.91 mm
Hg for WVV. P value indicates the significance of the log-rank test comparing low with high variability within each randomisation group.
doi:10.1371/journal.pone.0103169.g007
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drinking, and history of cardiovascular disease or diabetes. Hazard
ratios express the risk associated with a 1-SD increment in the level
or variability of blood pressure. In our main analyses, we used all
available blood pressure measurements during follow-up up to an
event to compute blood pressure level and variability. In sensitivity
analyses of VIM and WVV, we excluded the blood pressure
readings obtained during the first 6 months or 1 year after
randomisation [2], those obtained 6 months before an event, or
those obtained 6 months after randomisation and 6 months before
an event.
Results
Baseline characteristics
At randomisation, patients in the placebo (n=2297) and active-
treatment (n=2398) groups were similar (p$0.079) for distribu-
tion of sex, age, blood pressure, pulse rate, body mass index, serum
cholesterol, use of tobacco and alcohol, previous cardiovascular
complications, and antihypertensive treatment. Of 4695 partici-
pants, 3138 (66.8%) were women. Age averaged 70.2 (SD, 6.7)
years. Sitting blood pressure was 173.8 (10.0) mmHg systolic and
85.5 (5.9) mmHg diastolic.
Table 1 lists the characteristics of participants by fourths of the
SBP distribution at randomisation. Prevalence rates of previous
cardiovascular complications, diabetes, and antihypertensive
treatment before enrolment and mean values of age, body mass
index, blood glucose, and serum creatinine increased (p#0.019)
across the SBP categories. During the run-in period (table 1), visit-
to-visit blood pressure variability, as captured by SD, CV, MMD
and ARV increased with higher category of SBP before
randomisation (p,0.0001). VIM did not increase with higher
run-in SBP (p = 0.084). In all 4695 patients, the correlation
coefficients of VIM with SBP level were 0.01 (p = 0.59) during the
run-in period and 20.01 (p = 0.75) during follow-up after
randomisation. We therefore based our main analyses on VIM
as index of visit-to-visit variability. WVV during the run-in period
(table 1) increased with higher SBP (p,0.0001).
Changes in systolic blood pressure level and variability
The value of x to compute VIM was 0.847 in patients
randomised to placebo and 0.981 in the active-treatment group.
The correlation coefficients of SBP with VIM were 20.015
(p = 0.49) and 20.015 (p = 0.48) during follow-up on placebo or
active treatment; the corresponding correlation coefficients with
WVV were 0.12 and 0.071 (p#0.0006), respectively.
Treatment status at 2 years. Among patients continuing
double-blind medication, nitrendipine or matching placebo were
the only treatments given at 2 years (median follow-up) in 597
(58.9%) of 1014 randomised to active treatment and in 343
(39.6%) of 866 placebo patients. Among the patients in open
follow-up at 2 years, 65 (36.5%) of 178 randomly assigned to active
treatment and 157 (58.1%) of 270 in the placebo group were on
antihypertensive drugs. Antihypertensive treatment status was
Table 3. Hazard ratios associated with level and visit-to-visit variability of systolic blood pressure during follow-up.
Mortality Fatal plus non–fatal events
Predictor variable (SD) Model Total Cardiovascular Cardiovascular Stroke Cardiac
All patients (n = 4695)
SBP (,13.6 mm Hg) … 1.35 (1.19–1.54)1 1.69 (1.40–2.04)1 1.53 (1.36–1.73)1 1.62 (1.33–1.97)1 1.51 (1.30–1.76)1
VIM 1.35 (1.19–1.54)1 1.70 (1.41–2.05)1 1.53 (1.36–1.73)1 1.61 (1.32–1.97)1 1.51 (1.29–1.76)1
VIM (,5.5 units) … 0.94 (0.81–1.09) 0.82 (0.66–1.02) 0.91 (0.79–1.04) 1.04 (0.84–1.28) 0.84 (0.70–0.99)*
SBP 0.94 (0.81–1.09) 0.81 (0.66–1.01) 0.91 (0.80–1.04) 1.01 (0.82–1.25) 0.86 (0.72–1.02)
Placebo (n = 2297)
SBP (,13.5 mm Hg) … 1.29 (1.09–1.53){ 1.68 (1.30–2.18)1 1.46 (1.24–1.72)1 1.70 (1.27–2.26)` 1.42 (1.16–1.73)`
VIM 1.28 (1.08–1.53){ 1.67 (1.29–2.16)1 1.45 (1.23–1.71)1 1.70 (1.27–2.27)` 1.41 (1.15–1.72)`
VIM (,5.6 units) … 0.90 (0.73–1.10) 0.75 (0.56–1.01) 0.86 (0.72–1.03) 0.97 (0.73–1.28) 0.80 (0.63–1.02)
SBP 0.92 (0.74–1.13) 0.77 (0.57–1.04) 0.88 (0.73–1.05) 0.96 (0.72–1.28) 0.83 (0.65–1.05)
Active treatment (n = 2398)
SBP (,12.6 mm Hg) … 1.46 (1.15–1.83){ 1.80 (1.29–2.50)` 1.75 (1.42–2.15)1 1.69 (1.22–2.35){ 1.71 (1.30–2.26)`
VIM 1.46 (1.16–1.85){ 1.84 (1.32–2.56)` 1.77 (1.44–2.18)1 1.75 (1.24–2.45){ 1.71 (1.30–2.26)`
VIM (,5.2 units) … 0.95 (0.76–1.20) 0.86 (0.61–1.21) 0.91 (0.73–1.13) 1.00 (0.71–1.39) 0.87 (0.65–1.17)
SBP 0.93 (0.74–1.18) 0.80 (0.56–1.15) 0.88 (0.70–1.10) 0.87 (0.60–1.26) 0.89 (0.66–1.19)
Level (SBP) and visit-to-visit variability independent of the mean (VIM) were calculated from all blood pressure readings available from randomisation until the
occurrence of an endpoint or until the end of follow-up in patients without an event. Hazard ratios express the risk associated with a 1-SD increase in the predictor
variable and were stratified for centre and adjusted for randomisation group (all patients), sex, age, body mass index, heart rate, cholesterol, smoking and drinking, and
history of cardiovascular disease or diabetes. Model indicates which systolic index was entered into the models in addition to the studied predictor. SDs are
approximate, because the number of blood pressure readings available for analysis differed slightly depending on the timing of endpoints. An ellipsis signifies that in
addition to the studied predictor no additional systolic index was entered.
Significance of the estimates:
*P#0.05;
{P#0.01;
`P#0.001;
1p,0.0001.
doi:10.1371/journal.pone.0103169.t003
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undocumented in 88 (49.4%) and 81 (30.0%) patients, respective-
ly.
Blood pressure level and variability at 2 years. At 2 years
(figure 2), SBP had fallen (p,0.0001) by a mean (SD) of 13.6 (13.4)
mm Hg and 24.0 (12.4) mm Hg in the placebo and active-
treatment groups, respectively. VIM had increased (p,0.0001) by
1.99 (7.28) and 1.66 (6.56) units, respectively, whereas WVV had
decreased (p = 0.044) by 0.17 (3.10) mm Hg in the active-
treatment group but not significantly in placebo group, averaging
0.01 (3.24) mm Hg (p= 0.96). At 2 years, the mean between-group
differences were 10.5 mm Hg (CI, 9.5 to 11.5; p,0.0001) for SBP,
0.29 units (CI, 20.15 to 0.74; p = 0.20) for VIM, and 0.073 mm
Hg (CI, 20.13 to 0.27; p = 0.47) for WVV. At 4 years, the mean
between-group differences were 11.0 mm Hg (CI, 9.4 to 12.6; p,
0.0001) for SBP, 0.46 units (CI, 20.18 to 1.11; p = 0.16) for VIM,
and 0.22 mm Hg (CI, 20.07 to 0.52; p = 0.14) for WVV.
Monotherapy vs. combination therapy. The number of
patient-years on monotherapy with first-line treatment was 1754.0
(31.0%) on nitrendipine placebo and 3107.4 (51.4%) on active
nitrendipine. In patients remaining on monotherapy, the value of
x to compute VIM was 3.354 in the run-in period and 0.058 and
0.659 in patients during follow-up on placebo (n= 885) or active
nitrendipine (n = 1351), respectively. At 2 years, the mean
between-group differences were 3.9 mm Hg (CI, 2.6 to 5.2; p,
0.0001) for SBP, 0.29 units (CI, 20.32 to 0.91; p = 0.35) for VIM,
and 0.12 mm Hg (CI, 20.19 to 0.44; p= 0.44) for WVV
(figure 3).
Among patients proceeding to combination therapy, the value
of x to compute VIM was 3.192 in the run-in period and 0.791
and 0.975 in patients during follow-up on placebo (n= 1412) or
active nitrendipine (n = 1047), respectively. At 2 years, the mean
between-group differences were 10.9 mm Hg (CI, 9.6 to 12.3; p,
0.0001) for SBP, 20.52 units (CI, 21.13 to 0.09; p = 0.096) for
VIM, and 20.069 mm Hg (CI, 20.33 to 0.20; p = 0.61) for WVV
(figure 4).
Incidence of endpoints
The number of accumulated patient-years was 5650.8 and
6045.1 in the placebo and active-treatment group, respectively.
Table 2 lists the rates of the main endpoints. Active treatment
reduced the incidence of the composite cardiovascular endpoint,
fatal plus non-fatal stroke and fatal plus non-fatal cardiac events.
Within each treatment group, in analyses dichotomised by the
randomisation-group specific medians, low vs. high VIM was not
associated with different rates (p$0.14) of total or cardiovascular
mortality (figures 5 and 6) or cardiovascular (figure 7), cerebro-
vascular or cardiac events. Low vs. high WVV was associated with
higher rates of total and cardiovascular mortality (figures 5 and 6)
on active treatment (p#0.0003), but not on placebo (p$0.17),
while in both treatment groups incidence rates of cardiovascular
(figure 7), cerebrovascular or cardiac events did not differ (p$
0.095) according to low vs. high WVV.
Table 4. Hazard ratios associated with level and within-visit variability of systolic blood pressure during follow-up.
Mortality Fatal plus non–fatal events
Predictor variable (SD) Model Total Cardiovascular Cardiovascular Stroke Cardiac
All patients (n = 4695)
SBP (,13.6 mm Hg) … 1.35 (1.19–1.54)1 1.69 (1.40–2.04)1 1.53 (1.36–1.73)1 1.62 (1.33–1.97)1 1.51 (1.30–1.76)1
WVV 1.36 (1.19–1.55)1 1.70 (1.41–2.05)1 1.54 (1.36–1.73)1 1.61 (1.32–1.97)1 1.52 (1.30–1.77)1
WVV (,2.3 mm Hg) … 0.94 (0.76–1.15) 0.91 (0.68–1.21) 1.02 (0.86–1.21) 1.10 (0.84–1.45) 1.00 (0.80–1.26)
SBP 0.90 (0.73–1.11) 0.86 (0.65–1.14) 0.96 (0.81–1.15) 1.03 (0.78–1.36) 0.95 (0.76–1.19)
Placebo (n = 2297)
SBP (,13.5 mm Hg) … 1.29 (1.09–1.53){ 1.68 (1.30–2.18)1 1.46 (1.24–1.72)1 1.70 (1.27–2.26)` 1.42 (1.16–1.73)`
WVV 1.29 (1.09–1.54){ 1.70 (1.31–2.19)1 1.46 (1.24–1.72)1 1.67 (1.25–2.24)` 1.43 (1.17–1.75)`
WVV (,2.4 mm Hg) … 1.00 (0.73–1.37) 0.91 (0.60–1.38) 1.03 (0.80–1.33) 1.28 (0.87–1.88) 0.88 (0.61–1.26)
SBP 0.96 (0.71–1.30) 0.87 (0.59–1.28) 0.96 (0.75–1.23) 1.16 (0.79–1.71) 0.85 (0.60–1.20)
Active treatment (n = 2398)
SBP (,12.6 mm Hg) … 1.46 (1.15–1.83){ 1.80 (1.29–2.50)` 1.75 (1.42–2.15)1 1.69 (1.22–2.35){ 1.71 (1.30–2.26)`
WVV 1.53 (1.21–1.95)` 1.90 (1.36–2.67)` 1.77 (1.44–2.18)1 1.69 (1.22–2.35){ 1.71 (1.29–2.26)`
WVV (,2.3 mm Hg) … 0.78 (0.56–1.08) 0.83 (0.53–1.30) 0.97 (0.74–1.26) 0.90 (0.56–1.45) 1.11 (0.80–1.54)
SBP 0.70 (0.49–0.99)* 0.69 (0.41–1.14) 0.89 (0.68–1.18) 0.89 (0.55–1.43) 1.02 (0.72–1.44)
Level (SBP) and within-visit variability (WVV) were calculated from all blood pressure readings available from randomisation until the occurrence of an endpoint or until
the end of follow-up in patients without an event. Hazard ratios express the risk associated with a 1-SD increase in the predictor variable and were stratified for centre
and adjusted for randomisation group (all patients), sex, age, body mass index, heart rate, cholesterol, smoking and drinking, and history of cardiovascular disease or
diabetes. Model indicates which systolic index was entered into the models in addition to the studied predictor. SDs are approximate, because the number of blood
pressure readings available for analysis differed slightly depending on the timing of endpoints. An ellipsis signifies that in addition to the studied predictor no additional
systolic index was entered. Significance of the estimates:
*P#0.05;
{P#0.01;
`P#0.001;
1p,0.0001.
doi:10.1371/journal.pone.0103169.t004
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Figure 8. Two-year absolute risk of a cardiovascular endpoint in relation to level and variability. SBP, VIM and WVV denote systolic
blood pressure, visit-to-visit variability independent of the mean and within-visit variability. The analyses account for randomisation group and were
stratified for centre and standardised to the distributions (mean or ratio) of sex, age, body mass index, heart rate, cholesterol, smoking and drinking,
and history of cardiovascular disease or diabetes. In panels A and B, the risk functions span the 5th to 95th percentile interval of SBP and are plotted
for the 5th, 25th, 50th, 75th and 95th percentiles of VIM (panel A) or WVV (panel B). In panels C and D, the risk functions span the 5th to 95th
percentile interval of VIM or WVV and are plotted for the 5th, 25th, 50th, 75th and 95th percentiles of SBP. The p values are for the independent
effects of SBP (psbp) and VIM (pvim) or WVV (pwvv). np and ne indicate the number of patients at risk and the number of events.
doi:10.1371/journal.pone.0103169.g008
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Multivariable-adjusted analyses
In all patients, with stratification for centre and adjustments
applied for randomisation group, sex, age, body mass index, heart
rate, serum cholesterol, smoking and drinking, and history of
cardiovascular disease or diabetes, the on-treatment SBP was a
strong (p,0.0001) and consistent predictor of all endpoints under
study and retained its significance when Cox models also included
VIM (table 3) or WVV (table 4). SBP remained a strong
prognosticator in analyses confined to patients on placebo or
active treatment (tables 3 and 4). In multivariable-adjusted
analyses (table 3), VIM was not associated with the risk of any
endpoint (p$0.058), except for a borderline significant but inverse
association with the risk of cardiac endpoints in a model not
including SBP (p= 0.047). WVV (table 4) did not predict any
endpoint (p$0.14) with exception of an inverse association
(p = 0.042) with total mortality among actively treated patients in
a model including SBP. Figure 8 shows that the absolute risk of a
composite cardiovascular endpoint increased with level of SBP,
but was not associated with VIM or WVV.
Analyses with a time-dependent adjustment for proceeding to
combination therapy, produced results for VIM (table 5) and
WVV (table 6) consistent with those presented in tables 3 and 4,
respectively. Similarly, sensitivity analyses of VIM (table 7) and
WVV (table 8), from which we excluded blood pressure measure-
ments obtained within the first 6 or 12 months after randomisa-
tion, 6 months prior to an event, or those obtained 6 months after
randomisation and 6 months prior to an event were confirmatory.
Discussion
The novelty of our current study lies in the randomised double-
blind placebo-controlled assessment of the risk associated with
blood pressure variability and in accounting for blood pressure
level while assessing blood pressure variability as cardiovascular
risk factor. The key finding was that antihypertensive treatment
lowered blood pressure and the incidence of cardiovascular,
cerebrovascular and cardiac complications, but compared to
placebo it did not affect visit-to-visit or within-visit blood pressure
variability. In our current analysis, only blood pressure level, not
variability, can therefore explain the benefit conferred by
antihypertensive treatment. Kaplan-Meier survival estimates and
fully adjusted Cox models confirmed that blood pressure level, but
not visit-to-visit or within-visit variability predicted outcome. The
findings were consistent in the placebo and active-treatment
groups analysed separately.
Our manuscript differs substantially from previous publications
on the role of blood pressure variability as cardiovascular
prognosticator. First, our analyses followed the lines of randomisa-
tion in a double-blind placebo-controlled trial [15–17]. Without
the need of complex statistical modelling, figure 2 clearly
demonstrates that only level can explain the difference in
Table 5. Hazard ratios associated with level and visit-to-visit variability of systolic blood pressure during follow-up with additional
adjustment for proceeding to combination therapy as time-dependent variable.
Mortality Fatal plus non–fatal events
Predictor variable (SD) Model Total Cardiovascular Cardiovascular Stroke Cardiac
All patients (n = 4695)
SBP (,13.6 mm Hg) … 1.38 (1.20–1.58)1 1.69 (1.40–2.05)1 1.55 (1.37–1.76)1 1.65 (1.35–2.03)1 1.53 (1.31–1.79)1
VIM 1.38 (1.20–1.58)1 1.70 (1.40–2.06)1 1.55 (1.37–1.75)1 1.65 (1.35–2.03)1 1.52 (1.30–1.78)1
VIM (,5.5 units) … 0.94 (0.81–1.09) 0.81 (0.66–1.01) 0.90 (0.79–1.03) 1.03 (0.84–1.28) 0.83 (0.70–0.99)*
SBP 0.95 (0.82–1.10) 0.81 (0.66–1.01) 0.92 (0.80–1.05) 1.03 (0.83–1.27) 0.86 (0.72–1.02)
Placebo (n = 2297)
SBP (,13.5 mm Hg) … 1.29 (1.08–1.53){ 1.66 (1.28–2.15)` 1.48 (1.25–1.75)1 1.74 (1.29–2.35)` 1.44 (1.17–1.77)`
VIM 1.28 (1.07–1.52){ 1.64 (1.27–2.13)` 1.47 (1.24–1.74)1 1.74 (1.29–2.35)` 1.43 (1.16–1.76)`
VIM (,5.6 units) … 0.89 (0.72–1.10) 0.75 (0.56–1.01) 0.86 (0.71–1.03) 0.96 (0.72–1.28) 0.80 (0.63–1.02)
SBP 0.91 (0.74–1.13) 0.77 (0.57–1.04) 0.88 (0.73–1.06) 0.97 (0.72–1.30) 0.83 (0.65–1.05)
Active treatment (n = 2398)
SBP (,12.6 mm Hg) … 1.51 (1.19–1.91)` 1.82 (1.30–2.54)` 1.76 (1.43–2.17)1 1.73 (1.25–2.41){ 1.71 (1.29–2.26)`
VIM 1.51 (1.19–1.92)` 1.85 (1.32–2.59)` 1.77 (1.44–2.19)1 1.77 (1.26–2.49)` 1.70 (1.29–2.25)`
VIM (,5.2 units) … 0.96 (0.76–1.21) 0.85 (0.60–1.20) 0.90 (0.72–1.12) 1.01 (0.72–1.42) 0.86 (0.64–1.16)
SBP 0.95 (0.76–1.20) 0.80 (0.56–1.15) 0.88 (0.70–1.10) 0.90 (0.62–1.30) 0.88 (0.65–1.19)
Level (SBP) and visit-to-visit variability independent of the mean (VIM) were calculated from all blood pressure readings available from randomisation until the
occurrence of an endpoint or until the end of follow-up in patients without an event. Hazard ratios express the risk associated with a 1-SD increase in the predictor
variable and were stratified for centre and adjusted for randomisation group (all patients), sex, age, body mass index, heart rate, cholesterol, smoking and drinking,
history of cardiovascular disease or diabetes, and combination therapy as time-dependent covariable. Model indicates which systolic index was entered into the models
in addition to the studied predictor. SDs are approximate, because the number of blood pressure readings available for analysis differed slightly depending on the
timing of endpoints. An ellipsis signifies that in addition to the studied predictor no additional systolic index was entered.
Significance of the estimates:
*P#0.05;
{P#0.01;
`P#0.001;
1p,0.0001.
doi:10.1371/journal.pone.0103169.t005
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outcomes between the two treatment groups. Previous reports on
visit-to-visit variability analysed clinical trial data as cohort studies
[2,4,22,23] with [2,4,22] – or even without [22,23] – a design
variable in multivariable models coding for randomisation group.
Second, advocates of the role of blood pressure variability as
cardiovascular risk factor support the idea that stroke is the
outcome most likely associated with variability over and beyond
level of blood pressure [1,3,4]. Syst-Eur was powered to
demonstrate a between-group difference in the incidence of
stroke, the primary endpoint of the trial [15–17]. The wide-spread
introduction of stroke and coronary care units and the increasing
availability of invasive intravascular procedures and thrombolysis
dramatically reduced the case-fatality rate of most cardiovascular
complications of hypertension. Not accounting for non-fatal events
limits the generalizability of several reports [9,13]. Third, our
multivariable-adjusted Cox models analysed variability as a
continuous variable, avoiding the problem of categorisation
[1,2,9,23]. Fourth, cardiovascular endpoints are often preceded
by changes in blood pressure related to the subsequent compli-
cation. Such blood pressure changes should not be considered to
predict a complication, but are actually part of the imminent event
[24]. Sensitivity analyses of VIM (table 7) and WVV (table 8),
from which we excluded blood pressure measurements obtained
within the first 6 or 12 months after randomisation, 6 months prior
to an event, or those obtained 6 months after randomisation and 6
months before an event were confirmatory. Finally, we showed
that our main measure of visit-to-visit blood pressure variability
was independent of the mean.
Factors explaining the difference with previous studies [1–4,8–
14] are the analysis of the data according to the random allocation
of patients, the double blind design, the multivariable adjustment
including blood pressure level, the analysis of blood pressure
variability as a continuous rather than as a categorical variable,
and the implementation in Syst-Eur of a comprehensive quality
control programme of the blood pressure measurements [19]. We
do not believe that selection of patients with isolated systolic
hypertension, age, or use of nitrendipine as first-line antihyper-
tensive drug explain why in our study blood pressure variability
did not predict outcome. Indeed, the average blood pressure at
entry into ASCOT-BPLA [25] was 164.0/94.7 (SD, 18.0/10.4)
mm Hg. The SD indicates that a substantial number of ASCOT
patients must have had isolated SBP, as defined in our current
study (160–219/,95 mm Hg). In ASCOT-BPLA [25], 63% of
randomised patients were older than 60 years. In ASCOT-BPLA
[1], systolic VIM and WVV averaged 13.1 (5.2) units and 5.91
(0.02) mm Hg on atenolol and 11.1 (4.5) and 5.42 (0.02) mm Hg
on amlodipine with between-group differences of 1.99 units (CI,
1.93 to 2.05) and 0.49 mm Hg (CI, 0.44 to 0.54), respectively. In
Syst-Eur, systolic VIM and WVV averaged 10.2 (5.7) units and
3.34 (2.35) mm Hg on placebo and 10.2 (5.2) units and 3.29 (2.24)
mm Hg on active treatment with between-group differences of
0.01 units (CI, 20.30 to 0.33) and 0.05 mm Hg (CI, 20.08 to
Table 6. Hazard ratios associated with level and within-visit variability of systolic blood pressure during follow-up with additional
adjustment for proceeding to combination therapy as time-dependent variable.
Mortality Fatal plus non–fatal events
Predictor variable (SD) Model Total Cardiovascular Cardiovascular Stroke Cardiac
All patients (n = 4695)
SBP (,13.6 mm Hg) … 1.38 (1.20–1.58)1 1.69 (1.40–2.05)1 1.55 (1.37–1.76)1 1.65 (1.35–2.03)1 1.53 (1.31–1.79)1
WVV 1.38 (1.21–1.59)1 1.70 (1.41–2.06)1 1.56 (1.37–1.76)1 1.65 (1.35–2.03)1 1.53 (1.31–1.80)1
WVV (,2.3 mm Hg) … 0.93 (0.76–1.15) 0.90 (0.68–1.20) 1.02 (0.86–1.21) 1.10 (0.84–1.45) 1.00 (0.80–1.25)
SBP 0.90 (0.73–1.11) 0.86 (0.65–1.14) 0.96 (0.81–1.14) 1.03 (0.78–1.36) 0.95 (0.76–1.19)
Placebo (n = 2297)
SBP (,13.5 mm Hg) … 1.29 (1.08–1.53){ 1.66 (1.28–2.15)` 1.48 (1.25–1.75)1 1.74 (1.29–2.35)` 1.44 (1.17–1.77)`
WVV 1.29 (1.08–1.54){ 1.67 (1.29–2.17)` 1.48 (1.25–1.76)1 1.72 (1.27–2.32)` 1.45 (1.18–1.79)`
WVV (,2.4 mm Hg) … 0.99 (0.73–1.36) 0.90 (0.59–1.36) 1.02 (0.79–1.32) 1.27 (0.86–1.88) 0.88 (0.61–1.26)
SBP 0.96 (0.71–1.30) 0.86 (0.58–1.28) 0.96 (0.75–1.24) 1.17 (0.79–1.72) 0.85 (0.60–1.20)
Active treatment (n = 2398)
SBP (,12.6 mm Hg) … 1.51 (1.19–1.91)` 1.82 (1.30–2.54)` 1.76 (1.43–2.17)1 1.73 (1.25–2.41){ 1.71 (1.29–2.26)`
WVV 1.59 (1.24–2.03)` 1.92 (1.36–2.72)` 1.78 (1.44–2.20)1 1.73 (1.25–2.41){ 1.70 (1.28–2.26)`
WVV (,2.3 mm Hg) … 0.78 (0.56–1.09) 0.82 (0.52–1.28) 0.96 (0.73–1.26) 0.90 (0.56–1.46) 1.10 (0.79–1.53)
SBP 0.70 (0.50–0.99)* 0.69 (0.41–1.14) 0.89 (0.68–1.18) 0.91 (0.56–1.46) 1.02 (0.72–1.44)
Level (SBP) and within-visit variability (WVV) were calculated from all blood pressure readings available from randomisation until the occurrence of an endpoint or until
the end of follow-up in patients without an event. Hazard ratios express the risk associated with a 1-SD increase in the predictor variable and were stratified for centre
and adjusted for randomisation group (all patients), sex, age, body mass index, heart rate, cholesterol, smoking and drinking, history of cardiovascular disease or
diabetes, and combination therapy as time-dependent covariable. Model indicates which systolic index was entered into the models in addition to the studied
predictor. SDs are approximate, because the number of blood pressure readings available for analysis differed slightly depending on the timing of endpoints. An ellipsis
signifies that in addition to the studied predictor no additional systolic index was entered.
Significance of the estimates:
*P#0.05;
{P#0.01;
`P#0.001;
1p,0.0001.
doi:10.1371/journal.pone.0103169.t006
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0.18), respectively. These measures of variability were lower in
Syst-Eur than in ASCOT-BPLA [1]. However, use of nitrendipine
as the first-line antihypertensive agent in Syst-Eur cannot explain
the discordance between our findings and those reported for
ASCOT-BPLA, because in Syst-Eur VIM and WVV were similar
on active and placebo nitrendipine. In our study, the indexes of
variability increased after randomisation. Patients could be
randomised if during the single-blind placebo run-in period SBP
ranged from 160 mm Hg to 219 mm Hg and diastolic blood
pressure was below 95 mm Hg. These blood pressure criteria were
the averages of six readings, two at three consecutive run-in visits
approximately 1 month apart. After randomisation, these
constraints on SBP level disappeared, explaining the increase in
variability.
The current study must be interpreted within the context of some
potential limitations. First, Syst-Eur involved older patients with
isolated systolic hypertension, of whom only one third had a history of
previous cardiovascular complications. Our current observations
might not be generalizable to younger individuals, patients with more
serious cardiovascular disease, in whom blood pressure regulation is
often compromised, or patients with predominant diastolic hyper-
tension. Second, the Syst-Eur trial was terminated early at the second
interim analysis because of a significant reduction of stroke, while
recruitment was still on-going [15]. This explains why the number of
analysable patients dropped from 4695 to around 2500 in some
sensitivity analyses, from which blood pressure readings obtained
during specified follow-up periods were excluded. In spite of the loss
of power and the drop in significance levels, sensitivity analyses were
confirmatory. Finally, nitrendipine was the first-line drug in the
active-treatment group, and enalapril and hydrochlorothiazide were
used as add-on medications. However, at 2 years, close to 60% of
patients allocated active treatment were still on monotherapy with
nitrendipine. Findings in patients remaining on monotherapy and in
those proceeding to combination therapy and models that included a
time-dependent covariable coding for proceeding to combination
therapy produced consistent results. These observations confirm a
meta-analysis showing that drug class effects on blood pressure
variability persist when medications were used in combination [26].
In conclusion, in Syst-Eur, higher blood pressure level, but not
higher variability, predicted risk. Blood pressure level is a
reversible risk factor, overriding all other modifiable risk factors.
The suggestion to consider blood pressure variability as an
additional risk indicator and to reduce it by drugs [1,4] detracts
from what really matters in the management of hypertension, that
Table 7. Sensitivity analyses of the predictive value of visit-to-visit variability of systolic blood pressure with exclusion of varying
follow-up periods.
Mortality Fatal plus non–fatal events
Predictor variable (SD) Model Total Cardiovascular Cardiovascular Stroke Cardiac
Six months after randomisation (n$2974)
SBP (,13.3 mm Hg) … 1.11 (0.95–1.31) 1.40 (1.12–1.76){ 1.28 (1.09–1.50){ 1.33 (1.04–1.71)* 1.32 (1.09–1.62){
VIM 1.12 (0.95–1.32) 1.40 (1.11–1.76){ 1.28 (1.09–1.50){ 1.35 (1.05–1.74)* 1.31 (1.07–1.61){
VIM (,5.2 units) … 0.99 (0.83–1.18) 0.90 (0.69–1.17) 0.94 (0.79–1.13) 1.07 (0.82–1.40) 0.88 (0.70–1.11)
SBP 1.02 (0.85–1.22) 0.94 (0.72–1.23) 0.99 (0.83–1.19) 1.12 (0.85–1.48) 0.94 (0.75–1.19)
One year after randomisation (n$2451)
SBP (,13.6 mm Hg) … 1.01 (0.85–1.21) 1.23 (0.96–1.58) 1.15 (0.96–1.38) 1.37 (1.05–1.80)* 1.14 (0.91–1.44)
VIM 1.00 (0.83–1.20) 1.20 (0.93–1.56) 1.12 (0.93–1.35) 1.34 (1.02–1.76)* 1.12 (0.88–1.42)
VIM (,5.3 units) … 0.93 (0.76–1.14) 0.83 (0.62–1.12) 0.85 (0.70–1.04) 0.81 (0.59–1.11) 0.89 (0.69–1.14)
SBP 0.93 (0.76–1.14) 0.87 (0.64–1.18) 0.88 (0.72–1.08) 0.86 (0.62–1.20) 0.92 (0.71–1.19)
Six months before an event (n$3474)
SBP (,13.0 mm Hg) … 1.23 (1.05–1.45)* 1.55 (1.23–1.96)` 1.29 (1.10–1.52){ 1.42 (1.10–1.83){ 1.26 (1.03–1.55)*
VIM 1.23 (1.04–1.44)* 1.55 (1.22–1.95)` 1.29 (1.10–1.52){ 1.44 (1.11–1.86){ 1.23 (1.01–1.52)*
VIM (,5.2 units) … 0.94 (0.79–1.12) 0.88 (0.67–1.17) 0.93 (0.77–1.12) 1.08 (0.82–1.42) 0.81 (0.64–1.04)
SBP 0.98 (0.81–1.17) 0.94 (0.70–1.25) 0.98 (0.81–1.18) 1.13 (0.85–1.50) 0.85 (0.67–1.09)
Six months before an endpoint and six months after randomisation (n$2941)
SBP(,13.3 mm Hg) … 1.18 (0.99–1.40) 1.46 (1.15–1.86){ 1.23 (1.03–1.46)* 1.41 (1.08–1.84)* 1.20 (0.97–1.50)
VIM 1.17 (0.98–1.39) 1.43 (1.12–1.83){ 1.20 (1.01–1.43)* 1.39 (1.06–1.81)* 1.17 (0.93–1.46)
VIM (,5.2 mm Hg) … 0.91 (0.76–1.10) 0.78 (0.58–1.05) 0.82 (0.67–1.01) 0.84 (0.61–1.15) 0.83 (0.65–1.07)
SBP 0.95 (0.78–1.15) 0.83 (0.61–1.12) 0.86 (0.70–1.05) 0.89 (0.64–1.23) 0.87 (0.67–1.13)
SBP and VIM indicate level and variability independent of the mean of systolic blood pressure. Hazard ratios express the risk associated with a 1-SD increase in the
predictor variable and were stratified for centre and adjusted for randomisation group, sex, age, body mass index, heart rate, cholesterol, smoking and drinking, and
history of cardiovascular disease or diabetes. Model indicates which systolic index was entered into the models in addition to the studied predictor. SDs are
approximate, because the number of patients and blood pressure readings available for analysis differed slightly depending on the timing of endpoints. An ellipsis
signifies that in addition to the studied predictor no additional systolic index was entered.
Significance of the estimates:
*P#0.05;
{P#0.01;
`P#0.001.
doi:10.1371/journal.pone.0103169.t007
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is controlling the blood pressure level. In keeping with the recent
European guideline [7], blood pressure variability remains a
research instrument and requires further evaluation before it can
be meaningfully applied in clinical practice.
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